phase readout
saveNCT06031558: Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
ACTIVE_NOT_RECRUITINGupdated 20d ago
community read0 votes
Sponsor: Shouyao Holdings (Beijing) Co. LTD. Phase: PHASE3. Conditions: Non-Small Cell Lung Cancer
view source ↗
comments(0)
5-min edit window · permanent after that